Evaluation of [18F]-CP18 as a PET imaging tracer for apoptosis

  • Helen Su
  • , Gang Chen
  • , Umesh Gangadharmath
  • , Luis F. Gomez
  • , Qianwa Liang
  • , Fanrong Mu
  • , Vani P. Mocharla
  • , A. Katrin Szardenings
  • , Joseph C. Walsh
  • , Chun Fang Xia
  • , Chul Yu
  • , Hartmuth C. Kolb

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We identified and validated [18F]-CP18, a DEVD (the caspase 3 substrate recognition motif) containing substrate-based compound as an imaging tracer for caspase-3 activity in apoptotic cells. Procedures: CP18 was radiolabeled with fluorine-18 using click chemistry. The affinity and selectivity of CP18 for caspase-3 were evaluated in vitro. The biodistribution and metabolism pattern of [18F]-CP18 were assessed in vivo. [ 18F]-CP18 positron emission tomography (PET) scans were performed in a dexamethasone-induced thymic apoptosis mouse model. After imaging, the mice were sacrificed, and individual organs were collected, measured in a gamma counter, and tested for caspase-3 activity. Results: In vitro enzymatic caspase-3 assay demonstrated specific cleavage of CP18. In vivo, [ 18F]-CP18 is predominantly cleared through the kidneys and urine, and is rapidly eliminated from the bloodstream. There was a sixfold increase in caspase activity and a fourfold increase of [18F]-CP18 retention in the dexamethasone-induced thymus of treated versus control mice. Conclusions: We report the use [18F]-CP18 as a PET tracer for imaging apoptosis. Our data support further development of this tracer for clinical PET applications.

Original languageEnglish
Pages (from-to)739-747
Number of pages9
JournalMolecular Imaging and Biology
Volume15
Issue number6
DOIs
StatePublished - Dec 2013

ASJC Scopus Subject Areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Keywords

  • Apoptosis
  • Caspase
  • Molecular imaging
  • PET

Cite this